Rheumatology Highlights Report
Osteoporosis
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: December 29, 2011
Expiration Date: December 29, 2012
Estimated Time of Completion: 15 minutes
Description
The Rheumatology Highlights Report Series is designed for the busy clinician. It provides highlights from key scientific presentations and/or abstracts presented at the national rheumatology meeting. Clinical experts attending this meeting have selected the most significant data to report. Each activity is a 15-minute presentation. Enhancements include downloadable audio and slide sets, and supporting abstracts with expert commentaries. This series offer two methods of participation: on your computer or mobile device.
Learning Objectives
- Review new information on drug therapy for osteoporosis, including denosumab and teriparatide.
- Discuss adherence to therapy on intravenous bisphosphonates.
- Evaluate frequency of treatment in patients meeting 2008 National Osteoporosis Foundation guidelines.
- Consider use of bisphosphonates in glucocorticoid-induced osteoporosis.
Target Audience
This activity is directed to rheumatologists, immunologists, rheumatology and immunology fellows, clinical researchers, and rheumatology and immunology allied health professionals, including nurse practitioners and physician assistants.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R. J. Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Faculty
Chad Deal, MD
Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Head, Center for Osteoporosis and Metabolic Bone Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:
| Leonard H. Calabrese, DO | ||
| Abbott Laboratories; Amgen, Inc.; Centocor; Genentech/Roche; Pfizer | Consulting, Teaching & Speaking | |
| BMS; Elan Pharmaceuticals, Inc.; Wyeth | Consulting | |
| Chad Deal, MD | ||
| Amgen, Inc.; Lilly | Consulting; Teaching and Speaking; Membership on advisory committee or review panels |
|
The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants
for partial support of this activity from:
Amgen, Inc.
Pfizer, Inc.
Abbott Laboratories Inc.
Genentech & Biogen Idec
UCB, Inc.
Human Genome Sciences, Inc.
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and the R.J. Fasenmyer Center for Clinical Immunology.
